Inhibikase Therapeutics, Inc. (NYSE:IKT) Director Acquires $198,650.00 in Stock

Inhibikase Therapeutics, Inc. (NYSE:IKT) Director Arvind Kush purchased 145,000 shares of Inhibikase Therapeutics stock in a transaction that occurred on Monday, October 21st. The shares were bought at an average cost of $1.37 per share, for a total transaction of $198,650.00. Following the completion of the transaction, the director now directly owns 145,000 shares in the company, valued at $198,650. The purchase was disclosed in a document filed with the SEC, which is available through this link.

Inhibikase Therapeutics Price Performance

Inhibikase Therapeutics stock traded up $0.32 during midday trading on Wednesday, hitting $2.43. 470,766 shares of the company were exchanged, compared to its average volume of 183,455. The company’s fifty day moving average price is $1.39 and its 200-day moving average price is $1.51. The company has a market cap of $17.53 million, a PE ratio of -0.71 and a beta of 1.32. Inhibikase Therapeutics, Inc. has a fifty-two week low of $0.80 and a fifty-two week high of $3.82.

Inhibikase Therapeutics (NYSE:IKT) last announced its earnings results on Wednesday, August 14th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.08). On average, analysts expect that Inhibikase Therapeutics, Inc. will post -2.75 EPS for the current fiscal year.

Hedge Funds Weigh In On Inhibikase Therapeutics

An institutional investor recently bought a new position in Inhibikase Therapeutics stock. Armistice Capital LLC purchased a new stake in Inhibikase Therapeutics, Inc. (NYSE:IKT) in the second quarter, according to its most recent filing with the SEC. The fund purchased 589,575 shares of the company’s stock, valued at approximately $713,000. Armistice Capital LLC owned about 8.17% of Inhibikase Therapeutics at the end of the most recent quarter. 3.81% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reduced their price target on Inhibikase Therapeutics from $15.00 to $5.00 and set a “buy” rating on the stock in a research report on Monday, October 14th.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract.